A Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels

Simply Wall St.03-25 10:12

AdvertisementPfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and showing mixed returns over different periods, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622045336?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137","is_english":true,"pubTime":"2026-03-25 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622045336","market":"nz","top_or_hot":-1,"title":"A Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementPfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and showing mixed returns over different periods, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/a-look-at-pfizer-pfe-valuation-as-shares-trade-near-recent-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Pfizer (PFE) Valuation As Shares Trade Near Recent Levels\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 10:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/a-look-at-pfizer-pfe-valuation-as-shares-trade-near-recent-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementPfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and showing mixed returns over different periods, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/a-look-at-pfizer-pfe-valuation-as-shares-trade-near-recent-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0170899867.USD","symbol_name":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/a-look-at-pfizer-pfe-valuation-as-shares-trade-near-recent-l","article_id":"2622045336","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/162270-main-header/1756254067137"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/a-look-at-pfizer-pfe-valuation-as-shares-trade-near-recent-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622045336","pubTimestamp":1774404723,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pfizer overview and recent share performance\nPfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and showing mixed returns over different periods, including a 0.7% move in the latest session.\nOver the past week the share price shows a 1.8% decline, while roughly flat performance over the past month contrasts with a 7.7% gain in the past 3 months and a 13.2% total return over the past year.\nSee our latest analysis for Pfizer.\nFor you as a shareholder,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4007":"制药","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","PFE":"辉瑞","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4534":"瑞士信贷持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","BK4585":"ETF&股票定投概念","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK7095":"多种金属与采矿","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4568":"美国抗疫概念","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4550":"红杉资本持仓","BK4588":"碎股","SG9999002232.USD":"Allianz Global High Payout USD"},"translate_title":"辉瑞(PFE)股价接近近期水平时的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.98},"content_text":"AdvertisementPfizer overview and recent share performance Pfizer (PFE) has been on investors’ radar recently, with the stock last closing at US$26.96 and showing mixed returns over different periods, including a 0.7% move in the latest session. Over the past week the share price shows a 1.8% decline, while roughly flat performance over the past month contrasts with a 7.7% gain in the past 3 months and a 13.2% total return over the past year. See our latest analysis for Pfizer. For you as a shareholder, that means short term share price momentum has improved recently. However, the 1 year total shareholder return of 13.2% contrasts with weaker total returns over 3 and 5 years, so sentiment is rebuilding from a softer long term base. If you are tracking how healthcare names are moving alongside Pfizer, it could be a good moment to scan for other opportunities in medical technology and 36 healthcare AI stocks With Pfizer trading at US$26.96, an indicated intrinsic discount of 56.3% and a mixed record of recent returns, you might ask yourself whether this represents a genuine value opportunity or whether the market is already pricing in future growth. Most Popular Narrative: 12% Undervalued Pfizer's most followed narrative pegs fair value at $30.62 per share, above the last close at $26.96, which frames the stock as undervalued in that view and sets up a detailed turnaround story.  I think that Pfizer has a strong pipeline. The acquisition of Seagen added many new oncology products that will continue to grow by 14% partially offsetting the decline in sales of the COVID-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they're able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins etc.) and paying down debt, in the long term I see good annual returns (low double digits) from current stock price levels. There is risk for investors in the meantime! Pfizer's transition needs to happen fast otherwise Pfizer will have to borrow more money due to the capital nature of the business. Of course, this is not a capital light industry and Pfizer debt levels are already very high when we compare them with free cash flow to equity. Also, there is a risk of a dividend cut which would harm investors. Investors should be aware of these risks in this turnaround play.  Read the complete narrative. Curious what assumptions sit behind that $30.62 fair value tag. The narrative leans heavily on oncology growth, revenue stabilisation and margin power. It also bakes in a clear view on debt reduction and future profitability. The full breakdown shows exactly how those moving parts are stitched together into a long term valuation case. Result: Fair Value of $30.62 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points, including annual revenue and net income declines of 4.3% and 3.7%, plus a 19.2% negative 3 year total return that could challenge optimism. Find out about the key risks to this Pfizer narrative. Another View: Earnings Multiple Sends A Caution Signal The earlier fair value of $30.62 paints Pfizer as undervalued, but the current P/E of 19.8x tells a different story. That is higher than both the US Pharmaceuticals industry average of 16.5x and peer average of 17.9x, even though Pfizer scores only 3 out of 6 on valuation checks and its own fair ratio sits at 23.1x. In practice, that means you are paying a richer price than many sector alternatives today, while also sitting below a fair ratio level the market could theoretically move toward over time. Investors may wish to consider whether that is a reasonable trade off for the risks around earnings, cash flows and debt, or a signal to demand a wider margin of safety. See what the numbers say about this price — find out in our valuation breakdown. NYSE:PFE P/E Ratio as at Mar 2026Next Steps With sentiment clearly split between opportunity and risk, now is a good time to review the underlying data yourself and move with intent rather than hesitation. A balanced picture means weighing both sides, so it is worth checking the 1 key reward and 4 important warning signs Looking for more investment ideas? If Pfizer is only one piece of your watchlist, now is the moment to broaden your opportunity set with other stocks that fit clear, data driven filters.  Target potential mispricings by scanning companies that screen as attractively valued using the 58 high quality undervalued stocks. Prioritise resilience by reviewing companies that pass the 73 resilient stocks with low risk scores so you can focus on names with lower overall risk profiles. Hunt for future standouts by checking the screener containing 25 high quality undiscovered gems, where under-followed businesses with solid fundamentals are grouped for you.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622045336","isCrawlerRequest":true}